home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630673.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
32 lines
Document 0673
DOCN M9630673
TI The newer macrolides. Azithromycin and clarithromycin.
DT 9603
AU Zuckerman JM; Kaye KM; Temple University School of Medicine,
Philadelphia, Pennsylvania,; USA.
SO Infect Dis Clin North Am. 1995 Sep;9(3):731-45. Unique Identifier :
AIDSLINE MED/96087611
AB Azithromycin and clarithromycin are structural analogues of erythromycin
that have similar mechanisms of action. The newer macrolides have
several distinct advantages over erythromycin, including improved oral
bioavailability; longer half-life, allowing once or twice daily
administration; higher tissue concentrations; and fewer gastrointestinal
adverse effects. Clarithromycin and azithromycin also have enhanced
antimicrobial activity. The clinical efficacy of the newer macrolides
has been similar to erythromycin for the treatment of upper and lower
respiratory tract and skin and soft tissue infections. New therapeutic
roles include the use of azithromycin for C. trachomatis infections and
the inclusion of clarithromycin or azithromycin as part of therapeutic
regimens for disseminated MAC infections in HIV-infected patients.
Further clinical trials are needed to determine the optimal roles for
and uses of these new macrolides.
DE Antibiotics, Macrolide/*THERAPEUTIC USE Azithromycin/ADVERSE
EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Clarithromycin/ADVERSE
EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Drug Resistance, Microbial Human
Respiratory Tract Infections/DRUG THERAPY JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).